NASDAQ : PYPD

PolyPid Ltd. — Company profile

Healthcare · Biotechnology · Israel

Last price 5.39 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 109.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Details

NamePolyPid Ltd.
SectorHealthcare
IndustryBiotechnology
Employees75
Founded2008
Ipo Date2020-06-26
CeoDikla Czaczkes Akselbrad
CountryIsrael
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price16.00
IsinIL0011326795
CusipM8001Q126
Cik1611842
Sic3841

Key executives

NameTitle
Dalit HazanDeputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs
Dikla Czaczkes AkselbradChief Executive Officer and Director
Jonny MissulawinChief Financial Officer
Ori WarshavskyChief Operating Officer - US
Maria RubinExecutive Vice President of Operations
Tal VilnaiGeneral Counsel and Corporate Secretary
Rivi Lev-ariVice President of Human Resource
Dr. Jean-Marc Hagai Pharm.D.Chief Commercial Officer
Dr. Nurit Tweezer-Zaks M.B.A., M.D.Chief Medical Officer

Contact

Address18 Hasivim Street, Petah Tikva, 4959376, Israel
Phone972 7 4719 5700
Websitehttps://www.polypid.com